Curriculum Vitae

    Published Abstracts:
  1. Patak RV, Fadem SZ, Mauk RH, Lifschitz MD, and Stein JH. Attenuation of norepinephrine induced acute renal failure by renal vasodilatation. Kidney International 10:564, 1976
  2. Patak RV, Fadem SZ, Lifschitz MD, and Stein JH. The effect of diuretics on the initial phase of norepinephrine induced acute renal failure in the dog. Clinical Research 25:444A, 1977
  3. Patak RV, Fadem SZ, Lifschitz MD, and Stein JH. Studies on the mechanism of increased sodium excretion during drug induced vasodilatation. Kidney International 12:557, 1977
  4. Patak R, Rosenblatt S, Fadem S, Lifschitz M, and Stein J. Diuretic induced changes in renal prostagladin excretion. Kidney International 12:506, 1977
  5. Rosenblatt S, Lifschitz M, Welch R, Fadem S, and Stein J. Gastrointestinal blood loss and iron deficiency in patients on chronic hemodialysis. Kidney International 12:488m, 1977
  6. Lifschitz MD, Patak RV, Fadem SZ, and Stein JH. Chronic changes in renal sodium excretion and renal prostaglandin E production in the rabbit. Clinical Research 26:64A, 1978
  7. Patak R, Fadem S, Rosenblatt S, Lifschitz M, and Stein JH. Diuretic induced changes in renal prostaglandin E excretion. Clinical research 26:42A, 1978
  8. Schaefer PC, Fadem SZ, Lifschitz M, and Goldsmith RS. Hypercalcemia due to high serum dihydroxycholecalciferol (1,25-DHCC). Clinical Research 26:522A, 1978
  9. Schaefer PC, Lifschitz M, Fadem SZ, and Goldsmith RS. Radioimmunoassay of 1,25-dihydroxycholecaliciferol in patients with renal diseases. Endocrine Society, 1978
  10. Cabala D, Winkle S, Poindexter S, Hedberg AM, Fadem S.Implementation of an education program for nutrient/drug education. American Society of Parenteral & Enteral Nutrition. 14th Clinical congress, 1990, San Antonio, Texas
  11. Tuma SN, Fadem SZ, Suki WN. Most severe alkalosis in human (ph 7.98), resulting in cardiac arrest. Successful outcome after hemodialysis and IV HCI. 11th International Congress of Nephrology, 1990.
  12. S. Noor Rahman, K.J. Heifner, S.Z. Fadem, M.E. McIovr, R.M. Brenner, K.M.Powers, J.M. Ford; "Health Related Quality of Life (HRQOL) Improvements in Anemic Chronic Kidney Disease (CKD) Patients Treated with Darbepoetin Alfa (AranespTM)"; 2002 National Kidney Foundation (NKF) Clinical Nephrology Meetings, April 2002. (Chicago, IL).
  13. S. Noor Rahman, K.J. Heifner, S.Z. Fadem, M.E. McIovr, R.M. Brenner, K.M. Powers, J.M. Ford; "Treatment of Anaemia with AranespTM (Darbepoetin Alfa) Improves Health Related Quality of Life (HRQOL) in Patients with Chronic Kidney Disease (CKD)"; 39th Annual Meeting of the European Renal Associations (ERA) / European Dialysis and Transplantation Association (EDTA) Meetings, July 2002 (Copenhagen, DENMARK).
  14. Lawrence M. Spergel, Janet E. Holland, Stephen Z. Fadem, Charles J. McAllister, Eileen J. Peacock; "Elevated Static Intra-Access Pressure Ratio (IAPR) is not Indicative of Low Access Blood Flow (AF)"; J Am Soc Nephrol 14:53A, 2003.
  15. P. Qiu, O. Smolenski, S. Fadem, K.S. Kant, L. Borneman, R. Hippensteel, L.A., Williams, S. Moe, "Rapid Control of Secondary Hyperparathyroidism with Paracalcitol (Zemplar®) Capsule in Patients on Peritoneal Dialysis"; J Am Soc Nephrol 14:484A, 2003.
  16. Daniel Coyne, k.J. Martin, P. Qiu, M. Acharya, D. Batlle, S. Rosansky, H. Abboud, S. Fadem, L. Levine, O. Smolenski, M. Kaplan, L. Williams, S. Sprague."Paricalcitol (Zemplar®) Capsule Controls Secondary Hyperparathyroidism (SHPT) in Chronic Kidney Disease (CKD) Stages 3 and 4 Patients"; J Am Soc Nephrol 15:733A, 2004.
  17. DeAnna Cheek, I. Teitelbaum, E. Zawada, D. Echlin, L. Williams, S. Fadem. "Paricalcitol (Zemplar®) Capsule Reduced Elevated iPTH Levels Significantly in CKD Stages 3 and 4 Patients Regardless of Race, Gender, Age, Disease Severity and Diabetic Status." J Am Soc Nephrol 15:734A, 2004.
  18. Abraham J, Sika M, Dwyer J, Fadem S, Sinsakul M, Van Buren P, Weiner D. The Impact of Ferric Citrate, an Oral Phosphate Binder, on Mineral and Bone Metabolism Markers in Dialysis Patients. Poster Presentation, American Society of Nephrology Meetings, Atlanta GA 2013.
  19. Edelstein, S, Zhao, S, Lynae, P, Yang, Y, Silva, A, Bleyer, A, Fadem S, pergola, P, Tietjen D, Fishbane, S. Analysis from the OPTIMIZE Trial: Evaluating Options for Initiating Tenapanor in CKD Patients on Dialysis with Hyperphosphatemia. Poster Presentation, National Kidney Foundation Spring Clinical Meeting, Boston, MA, 2022
  20. Fishbane, S. Fadem, S, Yang, Y, Edelstein, S, Spiegel, D. Tenapanor Plus Phosphate Binder Reduces Interdialytic Weight Gain (IDWG) in Patients with CKD on Hemodialysis (PD) Post Hoc Analysis of the AMPLIFY Study. Poster Presentation, American Society of Nephrology Meetings, Orlando, FL 2022
    Publications:
  1. Allen JR, Fadem SZ, Schecter MP, Toussleng PV, and Lester B. Paseo Drug Rap, Paseo Center, 1972 (A monograph on drug abuse among teenagers).
  2. Vineyard GC, Fadem SZ, Drmochowskia J, Carpenter CB, and Wilson RE. Evaluation of corticosteroid therapy for acute renal allograft rejection. Surgery, Gynecology, and Obstetrics 138:229, 1974
  3. Mauk RH, Patak RV, Fadem SZ, Lifschitz MD, and Stein JH. Effect of prostaglandin E administration in a nephrotoxic and a vasoconstrictor model of acute renal failure. Kidney International 12:122-130, 1977
  4. Stein JH and Fadem SZ. The renal circulation. J.A.M.A 239:1308-1312,1978
  5. Lifschitz MD, Patak RV, Fadem SZ, and Stein JH. Urinary prostaglandin E excretion: Effect of chronic alterations in sodium intake and inhibition of prostaglandin synthesis in the rabbit. Prostaglandins 16:607-619,1978.
  6. Patak RV, Fadem SZ, Lifschitz MD, and Stein JH. A study of factors which modify the development of norepinephrine induced acute renal failure in the dog. Kidney International 15:227-237, 1979
  7. Patak RV, Fadem SZ, Lifschitz MD, and Stein JH. Diuretic-induced changes in renal blood flow and prostaglandin E excretion in the dog. Am J Physiol 236:F494-F500, 1979
  8. Sack KE, Bekheit S, Fadem SZ, and Vedrossian CW. Severe pulmonary vascular disease in systemic lupus erythematosus. Southern Medical Journal 72:1016-1018, 1979
  9. Fadem SZ and Lifschitz DM. Use of saralasin in end stage renal disease. Kidney International Supplement s93-S100, 1979
  10. Bardgette JJ and Fadem SZ. Multiple myeloma. The Science and Practice of Clinical Medicine, Vol VI. John Dietschy, Sr. (Editor) Grune and Stratton.1980, 343-344
  11. Fadem SZ and Lifschitz MD. Macroglobulinemia. The Science and Practice of Clinical Medicine, Vol VI. John Dietschy, Sr. (Editor) Grune and Stratton.1980, 343-344
  12. Lifschitz MD, Patak R, Fadem S, Rosenblatt S, Burns R, Epstein M, and Stein JH. Factors involved in the regulation of renal prostaglandin production. Prostaglandins in Cardiovascular and Renal Functions:: proceedings of the 20th annual A.N. Richards Symposium of the Physiological Society of Philadelphia. Alexander Scriabine, Allan M. Lefer And Frederick A. Kuehl, Jr (Editors) Spectrum Publications, 1980
  13. Fadem SZ, Hernandez-Llamas G, Patak RV, Rosenblatt SG, Lifschitz MD, and Stein JH. Studies on the mechanism of sodium excretion during drug-induced vasodilations in the dog. Journal of Clinical Investigation 69:604-610m 1982
  14. Rosenblatt SG, Drake S, Fadem S, Welch R, and Lifschitz MD.Gastrointestinal blood loss inpatients with chronic renal failure. American Journal of Kidney Diseases. 1:232-236, 1982
  15. Fadem SZ, Helping patients, renal staff gains access to information. Nephrology New and Issues, 12:38-9, 1998
  16. Fadem SZ, One Year Later. Peritoneal Diabetes International,19,509-11,1999
  17. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney International 61:1830-9, 2002
  18. Atef-Zafarmand A, Fadem S,Disaster nephrology: medical perspective. Adv Ren Replace Ther. 10104-16, 2003.
  19. Spergel LM, Holland JE, Fadem SZ, McAllister CJ, Peacock EJ.Static intra-access pressure ratio does not correlate with access blood flow. Kidney Int. 2004 Oct;66(4):1512-6.
  20. Fadem S.The need for computer-based patient education. Adv Chronic Kidney Dis. 12:335-8, 2005.
  21. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B,Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47(2):263-6, 2006
  22. Fadem SZ. Chronic kidney disease as it relates to heart disease in the cancer patient. In: Ewer MS, ed. Cancer and the heart. St. Louis: Decker, B.C., 2006
  23. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA; TARGET Investigators. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.Nephrol Dial Transplant. 2008 Jul;23(7):2311-8
  24. Fadem SZ and Moe SM. Management of chronic kidney disease mineral-bone disorder. Adv Chronic Kidney Dis. 14(1):44-53,2007
  25. Fadem SZ and Moe SM.(Journal Guest Editor) Editorial: Management of chronic kidney disease-mineral bone disorder. Adv Chronic Kidney Dis. 14(1):2,2007.
  26. Fadem, SZ, Spry, L and Yee, J(Journal Guest editor) Editorial:Clinical Practice Management Issues. Adv Chronic Kidney Dise. 15(1):3-6, 2008.
  27. Wintz, R, Rosenthal, B and Fadem, SZThe Physician Quality Reporting Initiative: practical approach to implementing quality reporting. Adv Chronic Kidney Dis. 15(1):56-63, 2008.
  28. Buettner, K and Fadem, SZThe Internet as a tool for the renal community. Adv Chronic Kidney Dis. 15(1):73-82, 2008.
  29. Fadem, SZ, Internet Resources for Nephrologists, In: Wilcox, C. ed. Therapy in Nephrology and Hypertension: A companion to Brenner & Rector's: The Kidney, WB Saunders, New York 2008
  30. Fadem SZ, Al-Saghir F, Zollner G, Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol. (4):319-24, 2008.
  31. Friedman A, Fadem S. Reassessment of Albumin as a Nutritional Marker in Kidney Disease. J Am Soc Nephrol.2010; 0: ASN.2009020213v1-ASN.2009020213 (online)
  32. Fadem SZ, Walker DR, Abbott G, Friedman AL, Goldman R, Sexton S, Buettner K, Robinson K, Peters TG.Satisfaction with renal replacement therapy and education: the American Association of Kidney Patients survey. Clin J Am Soc Nephrol. Mar;6(3):605-12,2011
  33. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators*. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Lancet. 2011 Jun 25;377(9784):2181-92.
  34. Friedman AN, Fadem SZ.Making Measures Count. Clin J Am Soc Nephrol Jun 6(6):1507-11, 2011.
  35. Fadem, SZState of the art: Chronic kidney disease education. Dialysis & Transplantation. Sep 40(9):397-400, 2011
  36. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group*. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011 Nov;58(5):729-36.
  37. EVOLVE Trial Investigators*, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012 Dec 27;367(26):2482-94.
  38. Fadem, SZ ed, Issues in Dialysis ed. Nova Publishers, New York, 2012
  39. Fadem, SZ, Issues in Dialysis, Milestones in Dialysis, Nova Publishers, New York, 2012
  40. Ozar DT, Kristensen C, Fadem SZ, Blaser R, Singer D, Moss AH.Nephrologists' Professional Ethics in Dialysis Practices. Clin J Am Soc Nephrol Dec, 2012 [Epub}
  41. Friedman AN, Fadem SZ A more cautious stance on nutritional supplementation for hypoalbuminemia is justified. Am J Kidney Dis. 2013 Feb;61(2):349
  42. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE; Collaborative Study Group* The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.. Am J Kidney Dis. 2015 May7;S072-6366
  43. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP; Collaborative Study Group*. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015 Feb;26(2):493-503.
  44. Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9.
  45. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 Jul 7;132(1):27-39.
  46. Fadem, SZReversing the Reversible in Essentials of Chronic Kidney Disease, p 17-25, Fadem S. Editor, Nova Science Publishers, Hauppauge, NY 2015
  47. Fadem, SZPreventing Chronic Kidney Disease in Essentials of Chronic Kidney Disease, p 27-41, Fadem S. Editor, Nova Science Publishers, Hauppauge, NY 2015
  48. Fadem, SZ, EditorEssentials of Chronic Kidney Disease, Nova Publishers, Hauppauge, NY 2015
  49. Yagil Y, Fadem SZ, Kant KS, Bhatt U, Sika M, Lewis JB, Negoi D; Collaborative Study Group*.Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2015 Sep;6(5):252-63
  50. Fadem, Stephen Z. Recommendations for Improving the Health Care System - Pharmacology. 4 Emory Corp. Governance & Accountability. 2017;4 Rev 61
  51. Tong A, Manns B, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, Crowe S, Van Biesen W, Winkelmayer WC, O'Donoghue D, Tam-Tham H, Shen JI, Pinter J,Larkins N, Youssouf S, Mandayam S, Ju A, Craig JC; SONG-HD Investigators*.Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop. Am J Kidney Dis. 2017 Jan;69(1):97-107
  52. Fadem, SZReversing the Reversible in Essentials of Chronic Kidney Disease, p 55-68, Fadem S. Editor, Nova Publishers, Hauppauge, NY 20158
  53. Fadem, SZPreventing Chronic Kidney Disease - An Overview in Essentials of Chronic Kidney Disease, p 69-92, Fadem S. Editor, Nova Science Publishers, Hauppauge, NY 2018
  54. Fadem, Stephen and Hellman, Richard Diabetic Nephropathy in Essentials of Chronic Kidney Disease, p 185-198, Fadem S. Editor, Nova Science Publishers, Hauppauge, NY 2018
  55. Caberto, Sheryl and Fadem, StephenGenetic Renal Tubular Disorders in Essentials of Chronic Kidney Disease, p 215-230, Fadem S. Editor, Nova Science Publishers, Hauppauge, NY 2018
  56. Fadem, Stephen Z. The Complex Relationship Between Iron Regulation, Obesity, and Anemia. p 173-184, in Management of Anemia - A Comprehensive Guide for Physicians, Provenzano, Robert et al. Springer Science+Media, New York, NY 2018
  57. Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017;45(3):257-266
  58. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 Nov 16;377(20):1930-1942
  59. Fadem, Stephen Z. Compresentive Review of Iron Therapy in Chronic Kidney Disease in Renal Replacement Therapy, Controversies and Future Trends, Moura-Neto, Jose Editor, Nova Publishers, Hauppauge, NY 2018
  60. Ju A, Unruh M, Davison S, Dapueto J, Dew MA, Fluck R, Germain M, Jassal SV, Obrador G, O'Donoghue D, Josephson MA, Craig JC, Viecelli A, O'Lone E, Hanson CS, Manns B, Sautenet B, Howell M, Reddy B, Wilkie C, Rutherford C, Tong A; SONG-HD Fatigue Workshop Collaborators. Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop Report.Am J Kidney Dis. 2018 Jul;72(1):104-112.
  61. Tong A, Manns B, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, Crowe S, Van Biesen W, Winkelmayer WC, O'Donoghue D, Tam-Tham H, Shen JI, Pinter J, Larkins N, Youssouf S, Mandayam S, Ju A, Craig JC; SONG-HD Investigators. Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop. Am J Kidney Dis. 2017 Jan;69(1):97-107.
  62. Kim S, Fadem S. Communication matters: Exploring older adults' current use of patient portals. Int J Med Inform. 2018 Dec;120:126-136.
  63. Viecelli Viecelli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators. Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access.Am J Kidney Dis. 2018 May;71(5):690-700.
  64. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 Jul 7;132(1):27-39.
  65. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE; Collaborative Study Group. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis. 2015 Sep;66(3):479-88.
  66. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-344.
  67. Walker AG, Sibbel S, Wade C, Moulton N, Marlowe G, Young A, Fadem SZ, Brunelli SM. SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States. Kidney Med. 2021 Mar-Apr;3(2):216-222.e1.
  68. Fadem SZ and Moura-Neto J, Editors, Issues in Kidney Disease - Dialysis - Editors Nova Science Publishers, Hauppauge, NY 2021
  69. Fadem SZ Milestones in Dialysis in Issues in Kidney Disease - Dialysis - Fadem, Stephen Z and Moura-Neto, Jose, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  70. Murthy BVR and Fadem SZ Editors, Issues in Kidney Disease - Transplantation - Editors Nova SciencePublishers, Hauppauge, NY 2021
  71. Fadem SZ Evaluation of the Living Kidney Donor and Kidney Paired Donation in Issues in Kidney Disease - Transplantation - Murthy, Bhamidipati V.R. Murthy, and Fadem, Stephen Z, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  72. Fadem SZ and Awan AA, Issues in Kidney Disease - Acute Kidney Injury - Editors Nova SciencePublishers, Hauppauge, NY 2021
  73. Fadem SZAcute Kidney Injury and COVID-19 in Issues in Kidney Disease - Acute Kidney Injury - Fadem, Stephen Z and Awan, Ahmed Arslan Yousef , Editors, Nova SciencePublishers, Hauppauge, NY 2021
  74. Fadem SZ and Anumudu SJ , Issues in Kidney Disease - Chronic Kidney Disease - Editors Nova SciencePublishers, Hauppauge, NY 2021
  75. Fadem SZ Reverse the Reversible in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  76. Fadem SZ Prevention of Chronic Kidney Disease in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  77. Fadem SZ Anemia in Chronic Kidney Disease in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  78. Fadem SZ Diabetic Nephropathy in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  79. Fadem SZ Kidney Stones in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova SciencePublishers, Hauppauge, NY 2021
  80. Caberto, SC and Fadem SZ Genetic Renal Tubular Disorders in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, Samaya Javed, Editors, Nova Publishers, Hauppauge, NY 2021
  81. Fadem SZ Aging and the Kidney in Issues in Kidney Disease - Chronic Kidney Disease - Fadem, Stephen Z and Anumudu, samaya Javed, Editors, Nova Science Publishers, Hauppauge, NY 2021
  82. Fadem SZ Staying Healthy with Kidney Disease, A Complete Guide, Springer-Nature, New York, 2022
  83. Fadem, SZ, Golper, T, Moura-Neto J, Complications in Dialysis - in press, Springer-Nature, New York, projected 2023
  84. Fadem, SZ, Understanding and Preventing Falls, Springer-Nature, New York, Projected 2023
  85. Fadem, SZ, Dialysis, Transplantation, and Work: Honoring Original Intent.Clin J Am Soc Nephrol.2022;17:1431-1432.
*Member: Study Group
    Patient Education Articles:
  1. Fadem, Stephen Z.As someone recently diagnosed with CKD, can I swim and exercise? Kidney Beginnings,1,1:2002.
  2. Fadem, Stephen Z.,Garney, Paul, RD, Smith, Bruce T.As someone with chronic kidney disease, are there any herbal products that may cause further damage to the kidneys? aakpRenalife,17,6:2002.
  3. Fadem, Stephen Z.My doctor told me that controlling my kidney disease means controlling my blood pressure. What does this mean? Kidney Beginnings,1,1:2002.
  4. Fadem, Stephen Z.Keeping Fit: Why Dialysis Patients Should Exercise aakpRenalife,18,4:2003.
  5. Fadem, Stephen Z. Can I feel blood being pumped during hemodialysis? aakpRenalife,19,2:2003.
  6. Fadem, Stephen Z.,Garney, Paul, RD, Smith, Bruce T.Are Herbal Products Risky For Chronic Kidney Disease Patients? Kidney Beginnings,2,1,2003.
  7. Fadem, Stephen Z.Is there a connection between protein leakage and cholesterol level? Kidney Beginnings,3,1:2004.
  8. Fadem, Stephen Z.What medicines should I avoid now that I have reduced kidney function? Kidney Beginnings,3,2:2004.
  9. Fadem, Stephen Z.Just how does the kidney handle medications and what happens when kidney function is not optimal? Kidney Beginnings,3,2:2004.
  10. Fadem, Stephen Z.What is GFR? Kidney Beginnings,3,3:2004.
  11. Fadem, Stephen Z.My access is infected. Now what? aakpRenalife,20,2:2004.
  12. Fadem, Stephen Z.Delaying Dialysis: Managing Reduced Kidney Function aakpRenalife,20,3:2004.
  13. Fadem, Stephen Z.Can dialysis affect my vision? aakpRenalife,20,5:2005.
  14. Fadem, Stephen Z.Can aluminum antiperspirants harm me? aakpRenalife,21,1:2005.
  15. Fadem, Stephen Z.Slowing the Progression of Kidney Disease Kidney Beginnings, 4,3:2005.
  16. Fadem, Stephen Z.Understanding Anemia in Chronic Kidney Disease Kidney Beginnings, 4,5:2005.
  17. Fadem, Stephen Z.Can Over-the-Counter Medications be Dangerous if I am Also Taking Prescribed Medications? Kidney Beginnings, 5, 1, 2006.
  18. Fadem, Stephen Z.Preparation for Dialysis - The AV Fistula Kidney Beginnings, 6:5, 2007.
  19. Fadem, Stephen Z.Why does salt cause high blood pressure? aakp Renalife, 23,5:2007.
  20. Fadem, Stephen Z.The FDA Black Box Warning for ESAs aakp Renalife, 23,6:2007.
  21. Fadem, Stephen Z.A Doctor Gets Sick. aakp Renalife, 23,12:2007.
  22. Fadem, Stephen Z.A Nephrologist as a Cancer Patient Finds Enlightenment in a Support Group. RSN Hope Library, 12-31-2007
  23. Fadem, Stephen Z.How Can I Calculate my GFR,Kidney Beginnings, 8,11: 2008.
  24. Fadem, Stephen Z.A Nephrologist as a Cancer Patient Finds Enlightenment in a Support Group, Kidney Times, January, 2008 - EasyLink Access #: 282
  25. Fadem, Stephen Z.Cover Story - Remembering Kris Robinson, aakp Renalife, 25,4:2009
  26. Fadem, Stephen Z.Medicines that Help Slow the Progression of Kidney Disease - Kidney Beginnings,5,9:2009
  27. Fadem, Stephen Z. How Stuff Works - An Inside Look at a Dialysis Machine. aakp Renalife, 26(5):10-12, 2010
  28. Fadem, Stephen Z. Slowing Kidney Disease. aakp Renalife, 29 Mar 2013
  29. Fadem, Stephen Z. AAKP Take My Advice September 19, 2013 The doctor becomes a patient
  30. Fadem, Stephen Z. Ask the Doc: The Flu Shot AAKP Renalife, 2019; 52 (6): 21-22
  31. Fadem, Stephen Z. Ask the Doc: What Foods Should I Eat or Avoid with Chronic Kidney Disease AAKP Renalife, 2020; 53 (1): 12-18
  32. Fadem, Stephen Z. Ask the Doc: Exercise in Chronic Kidney Disease and the Elderly, AAKP Renalife2020; 53 (3): 12-14
  33. Fadem, Stephen Z. How Are We Going To Open Up Safety? AAKP Renalife2020; 53 (4): 13-16
  34. Fadem, Stephen Z. Ask the Doc: An Update on COVID-19 AAKP Blog June 10, 2021
  35. Fadem, Stephen Z. What Kidney Patients Need to Know This Flu Season,AAKP Renalife 2021; 54 (5): 12-14
  36. Fadem, Stephen Z and Nguyen, Michelle (Misha). How to Reduce the Risk of Falling, AAKP Renalife May/June 2022
  37. Fadem, Stephen Z. Health and Safety Guidance for Patients Ready to Travel AAKP Blog December 8, 2022
    Meetings Attended:

    1975-1990


  1. American College of Physicians, National Meeting, San Francisco, 1975
  2. ACP-Post Graduate Course, Renal, Galveston, 1976
  3. American Heart Association, Post Graduate Course on Chronic Renal Failure, New Haven, 1977
  4. American College of Physicians, Post Graduate Course, Renal, San Antonio, 1977
  5. American Society of Nephrology, National Meeting, Washington, 1977
  6. American College of physicians, National Meeting, Boston, 1978
  7. American Society of Nephrology, National Meeting, New Orleans, 1978
  8. American Society of Nephrology, National Meeting, Washington, 1980
  9. American College of Physicians, National Meeting, Kansas City, 1981
  10. American Society of Nephrology, National Meeting, Chicago, 1982
  11. First International Congress on Cyclosporins, Houston, 1983
  12. American Society of Nephrology, National Meeting, Washington, 1983
  13. American Society of Nephrology, National Meeting, Washington, 1984
  14. American Society of Nephrology, National Meeting, Washington, 1986
  15. American Society of Nephrology, National Meeting, Washington, 1987
  16. Advanced Technical Symposium on Dialysis, Chicago, 1988
  17. PD Perspectives, Laguna Beach, 1988 American Society of Nephrology, National Meeting, San Antonio, 1988
  18. National Kidney Foundation, National Meeting, San Antonio, 1988
  19. Peritoneal Dialysis, National Meeting, Dallas, 1989
  20. Update 1989, National Kidney Foundation, Houston, 1989
  21. American Society of Nephrology, National Meeting, Washington, 1989
  22. National Kidney foundation, National Meeting, Washington, 1989

    23. 1990-2005


  23. Update 1991, National Kidney Foundation, Houston, 1991
  24. American Society of Nephrology, National Meeting, Baltimore, 1991
  25. National Kidney Foundation, National Meeting, Baltimore, 1991
  26. Peritoneal Dialysis, National Meeting, Seattle, 1992
  27. Update 1992, National Kidney Foundation, Houston
  28. National Kidney Foundation, National Meeting, Baltimore, 1992
  29. Health Care Under Clinton, Washington, 1993
  30. Update 1993, National Kidney Foundation, Houston
  31. American Society of Transplant Physicians, Houston, 1993
  32. Conference on Trauma and Renal Failure, Naharia, Israel, 1993
  33. International Congress of Nephrology, Jerusalem, 1993
  34. American Board of Quality Assurance and Utilization Review Physicians, Dallas, 1993
  35. ESRD Network 14 Meeting, Dallas, 1993
  36. National Kidney Foundation, Annual Meeting, Boston, 1993
  37. American Society of Nephrology, Annual Meeting, Boston, 1993
  38. National Kidney Foundation, Annual Meeting, Orlando, 1994
  39. American Society of Nephrology, Annual Meeting, Orlando, 1994
  40. International Congress of Nephrology, Madrid, 1995
  41. National Kidney Foundation, Update 1995, Houston, TX February 24, 1995
  42. National Kidney Foundation, Annual Meeting, San Diego, 1995
  43. American Society of Nephrology, Annual Meeting, San Diego, 1995
  44. National Kidney Foundation, Spring Clinical Meeting, Anaheim, 1996
  45. National Kidney Foundation, Annual Meeting, New Orleans, 1996
  46. American Society of Nephrology, Annual Meeting, New Orleans, 1996
  47. National Kidney Foundation, Spring Clinical Meeting, Dallas, 1997
  48. Update 1997, NKF Update Symposium, Houston, TX February 28, 1997
  49. ASAIO, Annual Meeting, Atlanta, 1997
  50. International Congress of Nephrology, Annual Meeting, Sydney, 1997
  51. Siggraph, Annual Meeting, Los Angeles, 1997
  52. National Kidney Foundation, Annual Meeting, San Antonio, 1997
  53. American Society of Nephrology, Annual Meeting, San Antonio, 1997
  54. National Kidney Foundation, Spring Clinical Meeting, Nashville, 1998
  55. ASAIO, Annual Meeting, New York City, 1998
  56. American Board of Quality Assurance and Utilization Review Physicians, Salt Lake City, October, 1999
  57. National Kidney Foundation, Annual Meeting, Miami Beach, Florida, 1999
  58. Update 2000, The Stephen Z. Fadem Update Symposium, Houston, TX March 10, 2000
  59. The Forum of ESRD Networks, National Meeting, Washington DC, 2000
  60. RPA, Annual Meeting, Washington DC, 2000
  61. National Kidney Foundation, Spring clinical Meeting, Atlanta, Georgia 2000
  62. Vascular Access for Hemodialysis, Biannual Symposium, San Antonio,Texas 2000
  63. American Society of Nephrology, Toronto, 2000
  64. Update 2001, The Stephen Z. Fadem Update Symposium, Houston, TX March 10, 2001
  65. RPA Annual Meeting, Washington DC, 2001
  66. National Kidney Foundation, Spring Clinical Meeting, 2001
  67. AAKP Annual Meeting, Memphis, Tennesee 2001
  68. American Society of Nephrology, San Francisco, California 2001
  69. International Society of Nephrology, San Francisco, California 2001
  70. International Foundation of Kidney Foundations, Los Angeles, California 2001
  71. Update 2002, The Stephen Z. Fadem Update Symposium, Houston, TX March 8, 2002
  72. Renal Physicians Association, Washington, D.C., 2002
  73. NKF Spring Clinical Meeting, Chicago, Illinois 2002
  74. AAKP Annual Meeting, Orlando, Florida 2002
  75. Sociedad Peruana de Nefrologia, Lima, Peru, 2002
  76. American Society of Nephrology, Philadelphia, Pennsylvania 2002
  77. Renal Physicians Association, Washington, D.C., 2003
  78. National Kidney Foundation, Spring Clinicals, 2003
  79. International Foundation of Kidney Foundations (IFKF), Amsterdam, 2003
  80. World Congress of Nephrology, International Society of Nephrology, Berlin, 2003
  81. Update 2003, The Stephen Z. Fadem Update Symposium, Houston, TX February 7, 2003
  82. American Association of Kidney Patients, New Orleans, Louisiana 2003
  83. American Society of Nephrology Annual Meeting, San Diego, Ca, November 12-17, 2003
  84. Update 2004, The Stephen Z. Fadem Update Symposium, Houston, TX February 20, 2004
  85. Renal Physicians Association, Baltimore, Maryland 2004
  86. National Kidney Foundation, Spring Clinicals, 2004
  87. International Foundation of Kidney Foundations, Adelaide, Australia 2004
  88. American Society of Nephrology Annual Meeting,St. Louis, Missouri, October 27-November 1, 2004
  89. AAKP Retreat, January, 2005
  90. Clinical Performance Measures Committee, Baltimore, Maryland 2005
  91. Be Active Board Ortho-Biotech, New York, New York 2005
  92. Update 20005, The Stephen Z. Fadem Update Symposium, Houston, TX February 18, 2005
  93. Renal Physicians Association, Washington, D.C., 2005
  94. National Kidney Foundation Spring Meeting, Washington, D.D., 2005
  95. American Association of Kidney Patients, Annual Meeting, Las Vegas, Nevada 2005
  96. American Society of Nephrology, Annual Meeting, Philadelphia, Pennsylvania November 8-13, 2005

    97. 2006-2011


  97. Update 2006, The Stephen Z. Fadem Update Symposium, Houston, TX February 24, 2006
  98. Renal Physicians Association, Baltimore, MD, 2006
  99. National Kidney Foundation, CM06, Baltimore, MD 2006
  100. International Federation of Kidney Foundations, Sicily 2006
  101. ERA-EDTA Annual Meeting, Glascow, Scotland, UK 2006
  102. International Society Peritoneal Dialysis, Annual Meeting, Hong Kong 2006
  103. American Association of Kidney Patients, Annual Meeting, Orlando, Florida 2006
  104. ASBMR (American Society of Bone and Mineral Research), Philadelphia, Pennsylvania 2006
  105. American Society of Nephrology, Annual Meeting, San Diego, Ca, November 14-19, 2006
  106. Update 2007, The Stephen Z. Fadem Update Symposium, Houston, TX February 16, 2007
  107. Forum of ESRD Networks, Baltimore, 2007
  108. RPA Annual Meeting, Baltimore, 2007
  109. National Kidney Foundation, CM.07, Orlando, 2007
  110. IFKF 8th Annual Meeting, April 16-19, 2007 Curitiba, Brazil,
  111. World Congress of Nephrology, April 20-24, 2007, Rio de Jainero, Brazil
  112. Harvard Quality Colloquium, August 19-22, 2007, Cambridge, Massachusetts
  113. AAKP (American Association of Kidney Patients) Annual Meeting, August 30-September 2,2007, St. Louis, Missouri
  114. ASBMR (American Society of Bone and Mineral Research), Honolulu, Hawaii September 16-22, 2007
  115. American Society of Nephrology, Annual Meeting, San Francisco, Ca October 31-November 5, 2007
  116. Update 2008, The Stephen Z. Fadem Update Symposium, Houston, TX March 1, 2008
  117. Forum of ESRD Networks, Baltimore, 2008
  118. RPA Annual Meeting, Austin, 2008
  119. AAKP Annual Meeting, Washington, DC, 2008
  120. American Society of Nephrology, Annual Meeting, Philadelphia, Pennsylvania November 4-9, 2008
  121. Update 2009, The Stephen Z. Fadem Update Symposium, Houston, TX February 27, 2009
  122. RPA Annual Meeting, Baltimore, 2009
  123. NKF SCM09, Nashville, 2009
  124. Forum of ESRD Networks, Baltimore, 2009
  125. Harvard 8th Annual Quality Colloquium, August 17-20, 2009, Cambridge, Massachusetts
  126. AAKP 36th Annual Meeting, Denver, Co, September 3-5, 2009
  127. ASBMR 31st Annual Meeting, Denver, September 11-15, 2009
  128. ASN Renal Week 42nd Annual Meeting, San Diego, October 27 - November 1, 2009
  129. Update 2010, The Stephen Z. Fadem Update Symposium, Houston, TX March 5, 2010
  130. Renal Physicians Association Annual Meeting, Baltimore, MD, March 12-15, 2010
  131. NKF Spring Clinical Meeting, Orlando, FL, April 13-17, 2010
  132. Harvard 9th Annual Quality Colloquium, August 16-19 2010, Cambridge, Massachusetts
  133. AAKP 37th Annual Meeting, Tampa, Fl, Sept 2-4, 2010
  134. ASN Renal Week, Denver, Co, November 16-21, 2010
  135. Renal Physicians Association Annual Meeting, Washington, DC, March 17-20, 2011
  136. NKF SCM 2011, Las Vegas, Nv, April 26-30, 2011
  137. AAKP 38th Annual Convention, Little Rock, Ar, August 25-28, 2011
  138. ASN Kidney Week, Philadelphia, PA, November 8-13, 2011

    139. 2012-2017


  139. Renal Physicians Association Annual Meeting, Washington, DC March 15-18, 2012
  140. RPA Annual Meeting - Workgroup - Ethics -, Mar 2012
  141. STRACK AMA Regional meeting - San Antonio, TX April 24-26, 2012
  142. NKF Spring Clinical Meeting, Washington, DC May 9-13, 2012
  143. AAKP Annual Meeting, Atlanta, GA August 9-11, 2012
  144. Sanofi Round Table Discussion - Diabetes - Time to Optimize Care and Quality, January 30-31, 2012
  145. NKF CKD Update Symposium, Houston, TX, Oct 12, 2012
  146. ASN Renal Week, San Diego, CA Oct 30-Nov 4, 2012
  147. RPA Annual Meeting, New Orleans, LA Mar 14-17, 2013
  148. NKF Spring Clinical Meeting, Orlando, FL April 2-6, 2013
  149. PRA National Coverage Advocacy Program, Washington, DC, June 8-9, 2013
  150. NKF CKD Update Symposium, Houston, TX, Oct 11, 2013
  151. ASN Renal Week, Atlanta, GA November 5-10, 2013
  152. ASBMR Annual Meeting, Houston, TX, September 12-15, 2014
  153. NCQA Diabetes Expert Panel Discussion, March 28, 2014
  154. RPA Annual Meeting, Baltimore, MD March 20-23, 2014
  155. NKF Spring Clinical Meeting, Las Vegas, NV April 22-26, 2014
  156. National Committee on Quality Assurance Diabetes Measurement Advisory Panel (DMAP) Washington, DC, (Webex), August 7, 2014
  157. AAKP Annual Meeting, Las Vegas, NV September 26-28,2014
  158. NKF CKD Update Symposium, Houston, TX, Oct 10, 2014
  159. ASN Renal Week, Philadelphia, PA November 11-16, 2014
  160. NCQA DMAP Meeting Washington, DC (Webex), January 6, 2015
  161. RPA Annual Meeting, Baltimore, MD March 19-22, 2015
  162. NKF Spring Clinical Meeting, Dallas, TX, March 25-29, 2015
  163. AAKP Annual Meeting, Nashville, Tennessee September 25-27, 2015
  164. NKF CKD Update Symposium, Houston, TX, Oct 9, 2015
  165. ASN Renal Week, San Diego, CA November 3-8, 2015
  166. NKF Spring Clinical Meeting, Boston, MA, March 27-29, 2016
  167. National Committee on Quality Assurance (NCQA), Washington, DC (WebEx), Diabetes Medical Expert Panel, August 12, 2016
  168. AAKP Annual Meeting,Nashville, September 23-25, 2016
  169. NKF CKD Update Symposium, Houston, TX, Oct 9, 2016
  170. ASN Renal Week, Chicago, IL, November 15-20, 2016
  171. RPA Annual Meeting, Nashville, Tennessee March 17-19, 2017
  172. NKF Spring Clinical Meeting, Orlando, Florida April 18-22, 2017
  173. ASN Kidney Week 2017, New Orleans, LA, November 2-5, 2017

    174. 2017-2023


  174. RPA 2018 Annual Meeting, Orlando, Florida March 15018, 2018
  175. NKF Spring Clinical Meeting, Austin, Texas April 10-14, 2018
  176. ASN Kidney Week 2018, San Diego, California October 23-28, 2018
  177. RPA 2019 Annual Meeting, Chicago, Illinois March 28-312019
  178. NKF Spring Clinical Meeting, Boston, Massachusetts May 9-12, 2019
  179. ASN Kidney Week 2019, Washington, DC November 5-10, 2019
  180. ASN Kidney Week 2020 (Virtual) October 19-25, 2020
  181. AAKP Annual Meeting (Virtual) September 24, 2021
  182. ASN Kidney Week 2021 (Virtual) Nov 4-7, 2021
  183. NKF Spring Clinical 2022 - Boston
  184. ASN Kidney Week 2022 - Orlando AAKP Annual Meeting (Virtual) 2022
  185. NKF Deep Dive - Mariott Med Center 2022
    Selected Presentations:
  1. Fadem S, Patak R, Lifschitz M, and Stein J. Studies on the mechanism of increased sodium excretion during drug induced vasodilatation. (Presented at the American Society of Nephrology Annual Meeting, Washington, 1977).
  2. Solez K, Munoz Z, Daugirdas J, Fadem S. CyberNephrology, National kidney Foundation, Spring Clinical Meeting, Dallas, 1997
  3. Fadem SZ. Vanguards in Nephrology Poster Session, ASAIO, Atlanta, 1997
  4. Solez K, Fogo A, Daugirdas J, Fadem S. CyberNephrology, National Kidney Foundation, Spring Clinical Meeting, 1998
  5. Vanguards in Nephrology, ASAIO, New York, 1998
  6. Internet Security, DCA Computer Conference, Scottsdale, 1998
  7. Hepatitis in Developing Countries, Nepal, 1998
  8. History of Computing, Nepal, 1998
  9. Fadem SZ and Kim Solez, Internet Security, via Netmeeting, Paris, 1998
  10. Fadem SZ and Kim Solez, Issues in Nephrology - Netmeeting Transplant Pathology Conference 1998
  11. Fadem SZ and Kim Solez, Netmeeting - Philadelphia to Houston, 1998
  12. Diabetic Nephropathy, Texas Medical Association, 1999
  13. Internet, Discussion Group AAKP, Tampa, 2000
  14. Understanding the Internet, HCFA, Washington, 2000
  15. PreESRD, Medicine Grand Rounds, VAMC Houston, 2002
  16. Pre-ESRD Education AAKP, Memphis 2001
  17. In-credible web sites, AAKP, Memphis 2001
  18. Fadem SZ, Solez K, Hales M, Zelchezitz Conference, Dubai (via internet) 2001
  19. Chronic Kidney Disease, IFKF, Los Angeles, California, 2001
  20. Vascular Calcification, Medicine Grand Rounds, VAMC Houston, 2002
  21. S. Noor Rahman, K.J. Heifner, S.Z. Fadem, M.E. McIovr, R.M. Brenner, K.M Powers, J.M. Ford; "Health Related Quality of Life (HRQOL) Improvements in Anemic Chronic Kidney Disease (CKD) Patients Treated with Darbepoetin Alfa (AranespTM)"; 2002 National Kidney Foundation (NKF) Clinical Nephrology Meetings, April 2002 (Chicago, IL).
  22. Lessons from Africa, American Association of Kidney Patients,Orlando 2002
  23. Chemistries Workshop, American Association of Kidney Patients,Orlando 2002
  24. CKD Evaluation Workshop, American Association of Kidney Patients, Orlando 2002
  25. Preventing CKD, Sociedad de Nefrologia Peru, Lima, Peru 2002
  26. Reducing Mortality, Sociedad de Nefrologia Peru, Lima, Peru 2002
  27. Vascular Calcification, Sociedad de Nefrologia Peru, Lima, Peru 2002
  28. The Internet as a Patient Teaching Tool, Sociedad de Nefrologia Peru, Lima, Peru 2002
  29. Vascular Calcification - Baylor Renal Grand Rounds, Houston, Texas 2003
  30. Breakfast with the Experts, National Kidney Foundation Spring Clinicals, San Diego, California 2003
  31. Using the Internet to Develop Educational Resources for Kidney Foundations, IFKF, Amsterdam, 2003
  32. The Need for CKD Education Around the World, IFKF, Amsterdam, 2003
  33. Erythropoiesis for Nephrologists, Baylor Renal Grand Rounds, 2004
  34. Making the Internet Practical, IFKF, Adelaide, Australia, 2004
  35. Computer Magic - Renal Grand Rounds Baylor College of Medicine, Houston, Texas October 20, 2004
  36. Arrhythmia Management in ESRD and the Use of AEDs. ANNA Fall Seminar, San Antonio, Texas October, October 2004
  37. Information Systems to Monitor CKD Patient Management - Renal Physicians Association, Washington, DC March 20, 2005
  38. Fabry Disease - Baylor Renal Grand Rounds/Biopsy Conference - Baylor College of Medicine, 2005
  39. Alports Syndrome - Baylor Renal Grand Rounds/Biopsy Conference - Baylor College of Medicine, 2005
  40. Kidney Beginnings: Living withReduced Renal Function - AAKP National Conference - Workshop, Las Vegas, Nevada September 2,2005
  41. An Introduction to Reduced Renal Function - AAKP National Conference - Conference, Las Vegas, Nevada September 3,2005
  42. Get Connected: Kidney Disease on the Internet - AAKP National Conference - Workshop, Las Vegas, Nevada September 3,2005
  43. Electronic Health Records: Barriers, Reality, Implementation - Texas American Association of Clinical Endocrinologists, Houston, Texas September 17, 2005
  44. KDEC, Panel Moderator and Presenter Health Care policy Issues - Baltimore - October 26-29, 2006
  45. National Kidney Foundation of Southeast Texas, Fadem Update Symposium, Early CKD Management, A Social, Financial and Clinical Perspective, February 16, 2007, Houston
  46. Renal Physicians Association Annual Meeting, Nephrology Practice in the Information Age - How to Invest in IT without going Broke March 18-20, Baltimore2006
  47. Renal Physicians Association Annual Meeting, Nephrology Practice in the Information Age - Finding the Right System For Your Practice March 18-20, Baltimore2006
  48. Lunch with the Experts - AAKP 33rd Annual Meeting, Orlando August 31 - Sept 3,2006
  49. Lunch with the Experts - AAKP 33rd Annual Meeting, Orlando August 31 - Sept 3,2006
  50. Kidney Beginnings Live - AAKP 33rd Annual Meeting,Orlando August 31 - Sept 3,2006
  51. National Kidney Foundation Spring Clinical Meeting, CM.07 - Workshop: Technology and CKD - Benefits and Barriers of a System, April 13, 2007 - Orlando, Florida April 13, 2007
  52. National Kidney Foundation Spring Clinical Meeting, CM.07 - Computing Kidney Disease - Making the System Yours - Orlando, Florida April 13, 2007
  53. International Federation of Kidney Foundations Annual Meeting, - Using the Internet to Implement Patient Education Strategies -Curitiba, Brazil, April 7,2007
  54. Baylor College of Medicine, Houston, Texas - Renal Grand Rounds - May 23, 2007
  55. Brown Bag Lunch, Spring Branch Independent School District Corporate Offices, Houston, Texas CKD Awareness - August 29, 2007
  56. Directors of Physical Education, Spring Branch Independent School District - Butler Stadium, Creating a CKD Curriculum for Students - August 29, 2007
  57. Forum Conference, Houston, Texas - Introduction to Chronic Kidney Disease - October 9, 2007
  58. Baylor College of Medicine, Houston, Texas - Renal Grand Rounds - October 10, 2007
  59. Lunch with the Experts - AAKP 34th Annual Meeting, St Louis, Mo August 30,2007
  60. Lunch with the Experts - AAKP 34th Annual Meeting, St Louis, Mo August 31,2007
  61. Patient lecture - AAKP 34th Annual Meeting, St Louis, Mo September 1,2007
  62. National Kidney Foundation of Southeast Texas, Fadem Update Symposium, Assessment and Treatment of Chronic Kidney Disease, March 1, 2008, Houston
  63. FMCSA Presentation, Arlington, VA, Expert Panel Recommendations, March 14, 2008
  64. Fact or Fiction - Dispelling Myths about Kidney Disease - AAKP 35th Annual Meeting, Washington, DC August 28, 2008
  65. Lunch with the Experts - The Connection Between Diabetes and Kidney Disease - AAKP 35th Annual Meeting, Washington, DC August 29,2008
  66. Lunch with the Experts - Chronic Kidney Disease - AAKP 35th Annual Meeting, Washington, DC August 30,2008
  67. Baylor College of Medicine, Houston, Texas - Renal Grand Rounds - From Genotype to Phenotype, MYH9 - January 21, 2009
  68. National Kidney Foundation of Southeast Texas, Fadem Update Symposium, Moderator - Disaster Preparation, February 27,2009, Houston
  69. Renal Physicians Association, Satellite Breakfast Symposium, Moving Beyond the ESA Controversy, Baltimore, March 22,2009
  70. Renal Physicians Association, A Tribute to Robert Schrier, Medal of Excellence Dinner, Baltimore, March 22,2009
  71. National Kidney Foundation, SCM09, Dialysis Workshop, Nashville, March 25, 2009
  72. Why Do I Have Reduced Kidney Function? - AAKP 36th Annual Meeting, Denver, Co Sept 3,2009
  73. Lunch with the Experts - Cancer and Kidney disease - AAKP 36th Annual Meeting, Denver, Co Sept 4,2009
  74. Lunch with the Experts - Understanding Restless Leg Syndrome - AAKP 36th Annual Meeting, Denver, Co Sept 5,2009
  75. Baylor College of Medicine, Houston, Texas - Renal Grand Rounds - The Health Care Ecosystem, December 30, 2009
  76. National Kidney Foundation of Southeast Texas, Fadem Update Symposium, You are what you eat, February 16, 2010, Houston
  77. AAKP Medal of Excellence, Honoring Tom Parker - Presentation March 13, 2010, Baltimore, MD
  78. National Kidney Foundation, SCM10, Dialysis Workshop, Orlando, April 13, 2010
  79. Stem Cells - AAKP 37th Annual Meeting, Tampa, Fl, Sept 3,2010
  80. Five Tests Every CKD Patient Should Know About - AAKP 37th Annual Meeting, Tampa, Fl, Sept 4,2010
  81. Lunch with the Experts - Health Economics What Every Patient Should Know- AAKP 37th Annual Meeting, Tampa, Fl, Sept 3,2010
  82. Lunch with the Experts - Fatigue in Kidney Patients - AAKP 37th Annual Meeting, Tampa, Fl, Sept 4,2010
  83. What Every Social Worker Should Know About the Expanded Bundle- Houston, September 16,2010
  84. Dialysis Workshop, Meaningful Use - National Kidney Foundation, SCM11, Las Vegas, Nv, April 26, 2010
  85. Ethics in Renal Medicine - Baylor College of Medicine, Renal Grand Rounds, Houston, February 9, 2011
  86. Risk Factors in Chronic Kidney Disease - Texas Medical Association Annual Meeting - Texmed, May 13, 2011
  87. Meaningful Use Webinar - Forum of ESRD Networks, July 26, 2011
  88. Risk Factors in Chronic Kidney Disease - Baylor College of Medicine/Michael DeBakey VA Medical Center Grand Rounds, August 8, 2011
  89. Preventing Kidney Disease - AAKP 38th Annual Meeting, Little Rock, Ar, August 26, 2011
  90. Effective Communication - AAKP 38th Annual Meeting, Little Rock, Ar, August 26, 2011
  91. Stem Cells - AAKP 38th Annual Meeting, Little Rock, Ar, August 27, 2011
  92. Lunch with the Experts - Cancer and Kidney Disease - AAKP 38th Annual Meeting, Little Rock, Ar, August 27, 2011
  93. Ethics Panel Discussion - RPA Annual Meeting, Washington DC, March 2012
  94. BCM Renal Grand Rounds, Michael Debakey VA Medical Center, Houston, TX Sudden Death in CKD May 6, 2013
  95. Annual Diabetic Conference, Texas A&M Health Science Center Coastal Bend, Corpus Christi, TX, Diabetic Nephropathy, July 12, 2013
  96. Methodist/BCM Renal Grand Rounds, Houston, TX APOL1 - Genetics and Biomarkers in CKD, February 12, 2014
  97. Annual Diabetic Conference, Texas A&M Health Science Center Coastal Bend, Corpus Christi, TX, Diabetic Nephropathy, July 25, 2014
  98. AAKP Annual Meeting Las Vegas, NV September 26, 2014 - Lunch with the Experts - Can I Slow the Progression of Kidney Disease
  99. AAKP Annual Meeting Las Vegas, NV September 27, 2014 Breakout Session - Preventing the Progression of Kidney Disease
  100. Medical World Americas Conference and Expo, Houston, TC April 29, 2015 Prevention of Kidney Disease
  101. AAKP Annual Meeting Nashville, TN September 25, 2015 - Lunch with the Experts
  102. AAKP Annual Meeting Nashville, TN September 16, 2015 speaker
  103. AAKP Annual Meeting Nashville, TN September 23, 2016 - Lunch with the Experts
  104. AAKP Annual Meeting Nashville, TC 2016 - September 24, 2016 speaker
  105. NKF CKD Update Symposium, Houston, TX, October 9, 2016 Patient Safety
  106. BCM Renal Grand Rounds, Houston, TX, December 28, 2016 Making Dialysis Safe
  107. Coastal Bend Health Education Center, Texas A&M, Corpus Christi, Texas 13th Annual Diabetes Conference, July 21, 2017, Diabetic Nephropathy
  108. American Society of Nephrology, Kidney Week, New Orleans, Louisiana November 3, 2017 Preparing for and Responding to Disasters
  109. APIC (Association for Professionals in Infection Control and Epidemiology), Minneapolis, Minnesota June 13-15, 2018 June 14 Disaster Recovery Infection Control Following Natural Disasters
  110. AAKP Annual Meeting Tampa, Florida Lunch with the Experts - How can I slow the progression of kidney disease, June 8, 2018
  111. AAKP Annual Meeting Tampa, Florida Breakout Session - Reverse the Reversible - Managing the early stages of CKD June 8, 2018
  112. AAKP Annual Meeting Tampa, Florida Lunch with the Experts - How can I slow the progression of kidney disease, June 9, 2018
  113. Renal Grand Rounds Baylor College of Medicine, Houston, Texas Pharmaceutical Problems and Solutions May 22, 2019
  114. DaVita Physician Leadership Meeting 2019. San Diego, California March 7, 2019 Disasters Happen! Are you Ready?
  115. AAKP Annual Meeting September 6-8, 2019 Washington, DC - Breakout Session A - An Update on Hypertension Management September 6, 2019
  116. AAKP Annual Meeting September 6-8, 2019 Washington, DC - Lunch with the Experts - Understanding Your Laboratory Values September 7, 2019
  117. AAKP Annual Meeting September 6-8, 2019 Washington, DC - Annual Dinner/Banquet - History of Nephrology, September 7, 2019
  118. NKF Patient Symposium Houston, Texas October 5, 2019 - Update on Hypertension 2019
  119. Coronavirus: Observations of Healthcare Systems Responses to Pandemic (Nonprofit, Private and VA) (07/17/2021) AAKP Online Presentation
  120. AAKP 46th Annual National Patient Meeting (Virtual) September 24, 2021 - Advancements in Diabetes Kidney Disease Treatment
  121. AAKP HealthLine Webinar: Stop the Itch: Understanding and Managing Chronic Kidney Disease-Associated Pruritus (CKD-aP June 3, 2022
  122. AAKP 47th Annual National Patient Meeting (Virtual) September 21, 2022- Wellness Break: Staying Healthy with Kidney Disease
  123. AAKP 47th Annual National Patient Meeting (Virtual) Recorded September 220, 2022-Advancing Care, REsearch, and Shared Decision Making Through Published Work
  124. NKF Deep Dive - Staying Healthy with Kidney Disease NKF-Serving Texas Presentation, Marriott Med Center, Houston, TX November 12, 2022
    Research Experience:

    Kidney Associates


  1. Ferrlicit; Phase 3 - Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran - This multicenter, crossover, randomized, double blind, placebo-controlled prospective comparative study was performed in hemodialysis.Role: Principle investigator. Sponsor:R&D. Date:1999-2000.
  2. Phase 3 - Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD - randomized, placebo-controlled trials conducted in patients with stages 3 and 4 CKD with SHPT. Role: Principle investigator. Sponsor:Abbott. Date:2002-2004 .
  3. Protocol AATML2003-A. A Phase 3, multicentered, two-arm, randomized study comparing the effects of AAT-023 solution and heparin on the incidence of catheter-related blood stream infections in tunnelled chronic central venous catheters for dialysis. Role: Principle Investigator. Sponsor: Ash Access Technology Dates: 27 May 2005 - Jun 2008.
  4. Clinical Trial PR00-06-014 (CHOIR) - Post Market - (terminated by Data Safety Committee) Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease- open-label, randomized trial to study the risks and benefits of the correction of anemia in patients with chronic kidney disease who were not receiving dialysis. Role: Principle investigator. Sponsor:Ortho-Biotech. Date: 17 Apr2002- 23 Aug 2005 .
  5. Rockwell RMTI-SFP4/5 409 Cruise 1 NCT01320202 - Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients - safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD) receiving hemodialysis.(CRUISE 1)(Rockwell). Role: Principle investigator. Sponsor:Rockwell. Date:2011-2015.
  6. SHARP - Study of Heart and Renal Protection After Market NCT00125593 - determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD)- University of Oxford England: Merck. Role: Principle investigator. Sponsor:Oxford/Merck. Date:2005-2012 .
  7. NCT00234871 Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease - determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy(TANDEM)(ABBOTT)Role: Principle Investigator. Sponsor: Abbott. Date: 2005-2008.
  8. BCI-CHI-147. A Phase IV, multi-center, open-label study to evaluate the appropriate initial dose of Hectorol Injection (doxercalciferol) when converting ESRD patients on hemodialysis from Zemplar (paricalcitol) Injection administered for treatment of secondary hyperparathyroidism. Role: Principle Investigator. Sponsor: Bone Care International. Dates: 15 NOV 2004 - 10 Mar 2006 .
  9. Hoffman-La-Roche ML20338. NCT00442416. A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients. Role: Principle Investigator. Sponsor: Hoffman La Roche. Dates: 27 February 2007 to 01 January 2008 (Stopped because of legal resions).
  10. Amgen20050182 E.V.O.L.V.E. - to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who are receiving dialysis. Role: Principle Investigator. Sponsor: Amgen. Dates: Sep 2006 - May 2012 .
  11. TROPICS 3&4 NCT00396032 NCT00396253 Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters.Role: Principle Investigator. Sponsor: Genentech. Dates: OCT 2006 - Dec 2008. Clin J Am Soc Nephrol. 2010 Apr; 5(4): 631–636. .
  12. KRX-101-301 NCT00130208 The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria. Role: Principle Investigator. Sponsor: Keryx Biopharmaceuticals. Dates: AUG 2005 - FEB 2008 Am J Kidney Dis. 2011 Nov;58(5):729-36. .
  13. FGCL-4592-060 NCT01750190 A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis. Role: Sub Investigator. Sponsor: FibroGen. Dates: NOV 2012 - JUN 2017.
  14. CREDENCE -NCT02065791 A Randomized, Double-Blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects with Type 2 Diabetes Mellitus and Diabetic Nephropathy. Role: Sub Investigator. Sponsor: Janssen. Dates:17 Feb 2014 - PRESENT
  15. Pioneer - NCT02156843 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dighydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes. Role: Primary Investigator.Sponsor:NephroGenex. Dates:JUN 2014-WITHDREW.
  16. OTSUKA-156-13-210 NCT02160145 A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease. Role: Principle Investigator. Sponsor: Otsuka . Dates:MAY 2014 - APR 2017.
  17. OTSUKA-156-13-211 NCT02251275 Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. Role: Principle Investigator. Sponsor: Otsuka. Dates: 25 SEP 2014 - November 27, 2019
  18. CKDOPPS Chronic Kidney Disease Outcomes And Practice Patterns Study. An International Study of Chronic Kidney Disease. Collecting medical information on 8,000-12,000 people with advanced kidney disease not on dialysis.Role: Sub-Investigator. Sponsor: Arbor Research. Dates:2015.
  19. REATA 402-C-1005 A Pharmacodynamic Study of Measured Glomerular Filtration 2014 Rate Assessed by TC99M-DTPA in Patient with Chronic Kidney Disease and Type 2 Diabetes. Role:Sub-investigator. Sponsor: Reata. Date:JAN 2012 - OCT 2013.
  20. Keryx 0502-307 NCT01554982 - A Long-Term Safety Extension Trial of ferric citrate in Patients with ESRD on Dialysis. Role: Primary Investigator. Sponsor: Keryx Biopharmaceuticals. Date: AUG 2013-AUG 2014.
  21. Amgen20110226 - NCT01652872 - START-CKD: Strategies using 2012-present Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease. Role: Sub Investigator. Sponsor: Amgen. Date:JUL 2012-OCT 2017.
  22. OVERTURE NCT01430494 A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression. Role: Primary Investigator. Sponsor: Otsuka. Date:2012-present. to Establish the Rate, Characteristics, and Determinants of Disease Progression 156-10-291 (Otsuka Pharmaceutical. Date: JUN 2011-OCT 2014.
  23. A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis Role: Sub-Investigator. Sponsor:FibroGen, Inc. Date:11 DEC 2012-Present
  24. Ferric Citrate Trial - NCT01191255 A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis. Sponsor: Keryx Biopharmaceuticals. Dates: OCT 2010 - FEB 2013
  25. AMG073 20020390 (TARGET) NCT00113945: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalcet. Role: Principle Investigator. Sponsor: Amgen. Dates: Jul 2003-10 May 2013.
  26. NESP990788 Phase 3B A study evaluating the initiation and titration of fixed doses of Novel Erythropoiesis Stimulating Protein (NESP). Therapy in subjects with chronic renal insufficiency (CRI). Role: Principle Investigator. Sponsor: Amgen. Dates: 2001 .
  27. NESP KDQOL Trial. Treatment of Anemia with Aranesp (darbepoetin alfa) Effect pm Health Related Quality of Life (HRQOL) in Patients with Chronic Kidney Disease (CKD) Role: Principle Investigator. Sponsor: Amgen. Dates: 2001 .
  28. PEARL 2 NCT00598442 Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis (PEARL 2): Sub Investigator. Sponsor: Affymax. Dates: NOV 2007-Dec 2009.
  29. Shire 404 - NCT00567723. Long term treatment of end stage renal disease patients with lanthanum carbonate (Fosrenol). Role: Sub-Investigator: Sponsor: Shire. Dates: APR 2006 - JUN 2016

    30. DaVita Clinical Research


  30. DAP-RENSE-0805 Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (RENSE) NCT01104662. Role:Principle Investigator. Sponsor: Cubist Pharmaceuticals LLC. Dates: Apr 2010 - Jun 2012.
  31. M10-967 The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary HyperparathyroidismRole:Principle Investigator. Sponsor:Abbott. Date: 2009-2011.
  32. KAI-4179-003. Role: A double-blind, randomized, placebo-controlled multiple ascending dose study to assess the safety, tolerability and efficacy of KAI-4169 (a Type 1 Calcimimetic - became Amgen416) in hemodialysis subjects with secondary hyperparathyroidism.Role: Principle Investigator. Sponsor: KAI Pharmaceuticals, Inc. Dates: 23 Jun 2011-
  33. Amgen20130213: 416 Study - A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis. Role: Principle Investigator. Sponsor: Amgen. Dates:11 AUG 2014 – Present.
  34. Amgen20120229: 416 Study - A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis. Role: Principle Investigator. Sponsor: AMGEN: Dates: 12 March 2013.
  35. Amgen20130231: 416 Study - A Multicenter Sing-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis. Role: Principle Investigator. Sponsor: Amgen. Dates: 08 JAN 2014 – 31 AUG 2015.
  36. Amgen20120360: 416 Study - NCT01896232 A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCI With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism. Role: Principle Investigator. Sponsor: Amgen. Dates: 06 FEB 2014 – JAN 2015.
  37. AEMD-IDE-2013. A clinical Safety Study of the Aethlon Hemopurifier in Chronic ESRD Patients with HCV Infection. Role: Principle Investigator until October 19, 2015 (Became advisor to corporation) Sponsor: Aethlon Medical Inc. Date:8 Dec 2014 - 19 Oct 2015.
  38. Amgen20130374: Study Protocol for the Validation of the Nausea/Vomiting Symptom Assessment (NVSA) Patient-Reported Outcome Instrument Among Chronic Kidney Disease Patients on Dialysis With Secondary Hyperparathyroidism. Role: Principle Investigator. Sponsor: Amgen. Dates:15 MAY 2014 - 2015.
  39. ROXADUSTAT D5740C00002: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat (HIF inhibitor) for the Treatment of Anemia in Dialysis Patients. Role: Principle Investigator. Sponsor: AstraZeneca. Dates:22 APR 2015 - Present.
  40. Cormedix (LOCK-IT-100): A Phase 3, prospective, multicenter, double-blind, randomized, active control study to demonstrate the safety and effectiveness of Neutrolin® in preventing catheter-related bloodstream infections in subjects receiving hemodialysis therapy as a treatment for end-stage renal disease. Role: Principle Investigator. Sponsor: Cormedix. Dates:21 JUN 2016 - Present
  41. REATA FALCON - NCT03918447 - A Trial of Bardoxolone Methyl in Patients with ADPKD - An international multi-center, 1:1 randomized, double-blind, placebo-controlled, Phase 3 trial Sponsor:Reata. Dates 17 APR 2019 - Present
  42. Ardelyx TEN-02-301 NCT03427125 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Sponsor: Ardelyx Date:19 JAN 2018
  43. Akebia 25 6548 0025 NCT03799627 Study of Vadadustat in Hemodialysis Patients with Anemia switching from Epoetin (Alfa (FO2RWARD-2) Sponsor: Akebia Date 3 DEC 2019
  44. Reata Eagle NCT03749447 An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Sponsor - Akebia